134 results
Page 4 of 7
6-K
EX-99.1
01x iwv9jtm
21 Mar 13
Live Filing
12:00am
6-K
EX-99.1
yycvdvjk4fqp pncnp53
20 Mar 13
Live Filing
12:00am
6-K
EX-99.1
fah803lzy9g1sko1
5 Feb 13
Teva Announces First Patient Enrolled In Largest Clinical Study to Date Evaluating Azilect® for Mild Cognitive Impairment In Parkinson’s Disease
12:00am
424B5
cp1145n4 f1m9w0d7s
14 Dec 12
Prospectus supplement for primary offering
12:00am
424B5
xws2we3 qo
13 Dec 12
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
9b0lci cj
10 Oct 12
Teva to Present Positive Data for Glatiramer Acetate 40 MG/1 ML Given Three Times Weekly for Relapsing-remitting Multiple Sclerosis
12:00am
6-K
t919xkkl
8 Aug 12
Current report (foreign)
12:00am
6-K
EX-99.1
zoec4t1vbvp46se2u ay
19 Jun 12
Live Filing
12:00am
6-K
EX-99.1
h1naara1 m4
19 Jun 12
More Than 15 Clinical, Pre-Clinical and Health Economics Studies Will Be Presented
12:00am
6-K
EX-99.1
s0j3j
21 Mar 12
Live Filing
12:00am
6-K
EX-99.1
tknvp
16 Mar 12
Live Filing
12:00am
424B5
pyj7eo1px5alcf u1i
8 Nov 11
Prospectus supplement for primary offering
12:00am
424B5
m8arz29fo9
7 Nov 11
Prospectus supplement for primary offering
12:00am
6-K
kcyi2ta0l
4 Aug 11
Current report (foreign)
12:00am
6-K
bsljgy 3j
3 May 11
Teva Pharmaceutical Industries Limited 6-K
12:00am
6-K
EX-2.1
hrbu2h kj
3 May 11
Teva Pharmaceutical Industries Limited 6-K
12:00am
6-K
bhrrkqnl
12 Apr 11
Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
12:00am
6-K
r3mz7smvqgu6
24 Mar 11
the Procter & Gamble Company and Teva Pharmaceutical Industries Form Consumer Health Care Partnership
12:00am